Variability of caffeine metabolism by CYP1A2 polymorphism in different populations
CYP1A2多型によるカフェイン代謝の集団間での変動 (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- 種別未確定
- 対象
- 未確定
- 出版年
- 記録なし
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 未確認
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/03
- 鮮度
- 確認期限内
- 確認段階
- 確認待ち
- 記録状態
- 公開
出版状態の注記
出版状態: 未確認
Europe PMC lookup failed; publication status remains unknown.
状態の根拠を見る →日本語要約(機械生成)
本研究は、CYP1A2遺伝子多型がカフェイン代謝に及ぼす影響を、5つの民族集団(白人、アフリカ系、アメリカ系、南アジア系、東アジア系)の210人を対象に、in silico解析により検討した。EFSAの2015年の評価では、カフェインの単回摂取200~400mgは健康への懸念がないとされたが、CYP1A2*1A(rs762551)の遺伝子型により、急速代謝型(AA)と緩徐代謝型(AC/CC)に分類され、代謝速度に個人差がある。本研究の目的は、民族間でカフェイン代謝に有意差があるか、最も影響を受けやすい個人を特定することである。結果として、遺伝子型分布の民族差が示唆され、緩徐代謝型の個人はカフェインの影響を受けやすい可能性が示された。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Abstract
In 2015, the European Food and Safety Authority (EFSA) evaluated the worldwide consumption of coffee to verify the potential use and abuse of caffeine by the population, with the aim to identify potential adverse effects on the human health. The conclusion of the survey was the following: single doses of caffeine up to 200/400 mg did not give to any concern in the population. Objectives: In 2015, the European Food and Safety Authority (EFSA) evaluated the worldwide consumption of coffee to verify the potential use and abuse of caffeine by the population, with the aim to identify potential adverse effects on the human health. The conclusion of the survey was the following: single doses of caffeine up to 200/400 mg wer not dangerous for the consumers. Methods: Caffeine is one of the most widely consumed substance and beverage in the world, showing not only benefits, as excellent source of antioxidants, but also offering to prevent inflammatory and oxidative stress-related diseases, including obesity, metabolic syndrome and type 2 diabetes. In the elderly people with several comorbidities, caffeine contributed to reduce several neurological disorders, such as senile dementia, Alzheimer’s and Parkinson’s disease, contributing to alleviate tremors and helping the memory loss in elderly subjects. Results: It is widely known CYP1A2 polymorphic enzyme (AA) (AC) (CC) is responsible for different levels in the caffeine metabolism, leading to a distinction in separate categories where CYP1A2*1A allele (AA) are "rapid" caffeine metabolizers, in contrast to carriers of the variant CYP1A2*1F who are "slow" caffeine metabolizers (AC-CC). In the absence of biological matrix, such as blood and urine, we performed in silicoanalysis of the genetic polymorphism CYP1A2*1A rs762551 distributed into five different ethnic groups of 210 subjects, including Caucasian, Africans, Americans, South Asians and East Asians. Conclusions: The goal of this study is to identify potential significant difference in metabolism of caffeine to verify the most susceptible individuals in five ethnic groups. Structured abstract Coffee is one of the most widely consumed beverage in the world although it is not free from various effects and in 2015 the exposure to caffeine and the intake of daily coffee has been regulated by EFSA. Guidelines and EFSA results demonstrated caffeine is easily metabolized in the majority of subjects, although fast metabolizers are advantaged in contrast to other individuals with a slow metabolism.
DOI 10.21203/rs.3.rs-3090935/v1
原文・出典を見る →